Cargando…
Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice
Topical calcineurin inhibitors (TCIs), commercially available since 2000–2001, are the first and only topical medications approved for chronic treatment of atopic dermatitis (AD) in pediatric patients and remain a welcomed alternative to topical corticosteroids. In January 2006, the US Food and Drug...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing AG
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669499/ https://www.ncbi.nlm.nih.gov/pubmed/23703374 http://dx.doi.org/10.1007/s40257-013-0020-1 |